Overview

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to compare the oral contraceptive (OC) SH T00658ID over Ortho Tri-Cyclen Lo administered for 13 cycles to healthy female volunteers between 18 and 50 years of age who request oral contraceptive protection. Subjects on a levonorgestrel (LNG), norgestimate (NGM), norethindrone or norethindrone acetate containing oral contraceptive in a 21-day regimen suffering from hormone withdrawal-associated symptoms such as pelvic pain or headache or both, and willing to continue OC use but to switch to SH T00658ID or Ortho Tri-Cyclen Lo.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Contraceptive Agents
Contraceptives, Oral
Dienogest
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Ethinyl Estradiol
Fluoroquinolones
Moxifloxacin
Nandrolone
Norgestimate, ethinyl estradiol drug combination
Polyestradiol phosphate